Wake Up to Urinate Too Often? Allergan’s Got Your Back.

FDA approves the first treatment to combat nighttime trips to the bathroom: a nasal spray that decreases urine production.

Noctiva / Image: Business Wire
Noctiva / Image: Business Wire

There’s nothing worse than leaving the warmth and security of your bed in the middle of the night to venture to the bathroom. A recent article from Endpoints News has the answer to our prayers: a nasal spray that inhibits urine production at night. The drug is called Noctiva; it was developed by Allergan and then signed over to Serenity Pharmaceuticals in a commercialization deal.

The drug works by increasing urine absorption in the kidneys with a dose taken 30 minutes before bedtime to limit the effect to just nighttime. The drug will soon hit shelves with a black box label warning that notes the risk of dangerously low sodium levels. The drug passed an FDA vote 14-4, but some experts expressed concern that the drug could be dangerous for elderly patients with congestive heart failure or hypertension.

Fresh from the show floor: pharma packaging innovations for 2026
Serialization mandates. Containment demands. Sterile barrier requirements. Our editors found the pharma packaging innovations addressing your biggest challenges at PACK EXPO Las Vegas. Get your free curated report now.
GET YOUR COPY
Fresh from the show floor: pharma packaging innovations for 2026
Recyclable pill bottles are gaining pharmacy ground
Aluminum and paper-based prescription bottles are moving from concept to commercial reality. Here's what pharmacy and packaging leaders need to know.
Read More
Recyclable pill bottles are gaining pharmacy ground